

Grzegorz Helbig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8953870/publications.pdf>

Version: 2024-02-01

81
papers

864
citations

567247

15
h-index

552766

26
g-index

81
all docs

81
docs citations

81
times ranked

1269
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1109.	2.4	11
2	Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 408.e1-408.e6.	1.2	6
3	Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG). <i>Cancers</i> , 2021, 13, 4189.	3.7	6
4	Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. <i>Blood Reviews</i> , 2021, 49, 100809.	5.7	18
5	The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4584.	2.4	5
6	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 105-113.	0.4	3
7	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020, 34, 283-292.	7.2	48
8	Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. <i>Advances in Medical Sciences</i> , 2020, 65, 429-436.	2.1	2
9	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	5.2	39
10	The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 661-666.	0.6	6
11	Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1845-1853.	1.8	10
12	Antimicrobial prophylaxis in patients after hematopoietic cell transplantation: results of a survey of the Polish Federation of Bone Marrow Transplant Centers. <i>Acta Haematologica Polonica</i> , 2020, 51, 183-186.	0.3	1
13	Multiple tyrosine kinase inhibitors before allogeneic stem cell transplantation for chronic myeloid leukemia: toxicity and efficacy in a single center experience. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 553-556.	0.4	0
14	Multiparameter flow cytometry for assessment of minimal residual disease in patients with myelodysplastic syndromes treated with allogeneic stem cell transplantation. <i>Acta Haematologica Polonica</i> , 2020, 51, 88-94.	0.3	0
15	Exquisite response to imatinib mesylate in FIP1L1-PDGFR α -mutated hypereosinophilic syndrome: a very long-term experience of Polish Hypereosinophilic Syndrome Study Group. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 255-257.	0.4	2
16	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
17	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs FLAG-M) in Acute Myeloid Leukemia (AML) Patients \geq 60 Years Old (PALG-AML1/2016). <i>Blood</i> , 2020, 136, 3-4.	1.4	0
18	Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis: Relationship with Disease Activity and Type of Immunosuppressive Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 625.	2.4	12

#	ARTICLE	IF	CITATIONS
19	Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience. <i>Annals of Hematology</i> , 2019, 98, 1477-1483.	1.8	3
20	Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis. <i>Medical Oncology</i> , 2019, 36, 16.	2.5	19
21	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMENSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	1.3	11
22	Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. <i>Pathology and Oncology Research</i> , 2019, 25, 1175-1180.	1.9	15
23	Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 1709-1714.	2.2	10
24	Imatinib for the treatment of hypereosinophilic syndromes. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 163-170.	3.0	21
25	Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis. <i>Pathology and Oncology Research</i> , 2018, 24, 469-475.	1.9	5
26	Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. <i>PLoS ONE</i> , 2018, 13, e0204290.	2.5	15
27	Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors. <i>Medical Oncology</i> , 2018, 35, 119.	2.5	15
28	Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene. <i>Medical Oncology</i> , 2017, 34, 31.	2.5	1
29	Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenström's Macroglobulinemia. <i>Turkish Journal of Haematology</i> , 2017, 34, 186-187.	0.5	4
30	Safety and outcome of allogeneic stem cell transplantation in myelofibrosis. <i>European Journal of Haematology</i> , 2016, 96, 222-228.	2.2	2
31	Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance— Extended follow-up. <i>European Journal of Internal Medicine</i> , 2016, 35, e14-e15.	2.2	5
32	Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 62-65.	0.6	2
33	Safety and efficacy of hematopoietic stem cells mobilization in patients with multiple sclerosis. <i>Hematology</i> , 2016, 21, 42-45.	1.5	6
34	Profile of serum biomarkers in eosinophilic disorders. <i>European Journal of Internal Medicine</i> , 2016, 29, e19-e20.	2.2	0
35	Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?. <i>European Journal of Internal Medicine</i> , 2016, 32, e19-e20.	2.2	6
36	Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis — whom, when and how. <i>International Journal of Neuroscience</i> , 2016, 126, 867-871.	1.6	5

#	ARTICLE	IF	CITATIONS
37	Imatinib discontinuation for hypereosinophilic syndrome harboring the <i>FIP1L1-PDGFR</i> transcript. <i>Leukemia and Lymphoma</i> , 2016, 57, 708-710.	1.3	9
38	HLA Class I-Specific Effects in AML with Mutated Nucleophosmin. <i>Blood</i> , 2016, 128, 5230-5230.	1.4	1
39	Jak postÄ™pujemy u chorego z zespoÅ,em hipereozynofilowym?. <i>Acta Haematologica Polonica</i> , 2015, 46, 142-148.	0.3	0
40	Aggregates of pseudo-Gaucher cells after treatment of chronic myeloid leukemia in blastic phase. <i>International Journal of Hematology</i> , 2015, 101, 3-4.	1.6	4
41	Fungal Colonization of the Respiratory Tract in Allogeneic and Autologous Hematopoietic Stem Cell Transplant Recipients: A Study of 573 Transplanted Patients. <i>Medical Science Monitor</i> , 2015, 21, 1173-1180.	1.1	6
42	Cardiovascular dysfunction as a common cause of mortality in hypereosinophilic syndromes. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 692-694.	0.4	1
43	Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience. <i>Medical Oncology</i> , 2014, 31, 310.	2.5	1
44	Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in <i>FIP1L1-PDGFR</i> mutated hypereosinophilic syndrome. <i>American Journal of Hematology</i> , 2014, 89, 115-115.	4.1	18
45	Advances in the diagnosis and treatment of eosinophilia. <i>Current Opinion in Hematology</i> , 2014, 21, 3-7.	2.5	13
46	Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-4.	0.3	1
47	Idiopathic, asymptomatic, and durable blood hypereosinophiliaâ€”still many unknowns. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 932-933.	2.9	5
48	Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance. <i>Medical Oncology</i> , 2014, 31, 815.	2.5	16
49	Hairy cell leukemia and multiple myeloma: Two distinct entities or a single two-phase disease. <i>Acta Haematologica Polonica</i> , 2014, 45, 86-88.	0.3	0
50	Favorable Results of Allo-HSCT from MRD in Patients with Myelofibrosis. <i>Blood</i> , 2014, 124, 5934-5934.	1.4	0
51	Richter's Syndrome manifested as diffuse large B-cell lymphoma of the mandible with lytic lesions and hypercalcemic crisis. <i>Acta Haematologica Polonica</i> , 2013, 44, 409-412.	0.3	1
52	Myeloid neoplasms with eosinophilia and <i>FIP1L1-PDGFR</i> fusion gene: another point of view. <i>Leukemia and Lymphoma</i> , 2013, 54, 897-898.	1.3	5
53	Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients. <i>Leukemia and Lymphoma</i> , 2013, 54, 807-811.	1.3	31
54	Very poor outcome of leukemic transformation in myelofibrosis: a single center experience with 13 patients. <i>Leukemia and Lymphoma</i> , 2012, 53, 1236-1238.	1.3	2

#	ARTICLE	IF	CITATIONS
55	An extremely rare lineage switch from T-cell lymphoblastic lymphoma into B-cell acute lymphoblastic leukemia at relapse. <i>Acta Haematologica Polonica</i> , 2012, 43, 369-371.	0.3	0
56	The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. <i>Medical Oncology</i> , 2012, 29, 2379-2384.	2.5	10
57	Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation. <i>Wspolczesna Onkologia</i> , 2012, 3, 215-217.	1.4	4
58	Chronic eosinophilic leukemia— not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. <i>American Journal of Hematology</i> , 2012, 87, 643-645.	4.1	67
59	Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFR β -negative hypereosinophilic syndrome. <i>Medical Oncology</i> , 2012, 29, 1073-1076.	2.5	22
60	Imatinib mesylate for lymphocytic variant of hypereosinophilic syndrome. <i>American Journal of Hematology</i> , 2012, 87, 337-337.	4.1	1
61	Is it time for erythropoietin use in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients?. <i>Chinese Clinical Oncology</i> , 2012, 1, 22.	1.2	0
62	Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFR β -positive chronic eosinophilic leukaemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 967-969.	2.3	24
63	Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia. <i>Medical Oncology</i> , 2011, 28, 1601-1603.	2.5	5
64	Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFR α transcript after therapy with imatinib. <i>Leukemia Research</i> , 2011, 35, e15-e17.	0.8	2
65	Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. , 2011, 121, 44-52.		4
66	Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFR α fusion transcript— results of Polish multicentre study. <i>Hematological Oncology</i> , 2010, 28, 93-97.	1.7	19
67	Heterogeneity among characteristics of hypereosinophilic syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1399-1401.e2.	2.9	10
68	Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFR α fusion transcript: extended follow-up. <i>British Journal of Haematology</i> , 2009, 145, 132-134.	2.5	15
69	T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. <i>Haematologica</i> , 2009, 94, 1236-1241.	3.5	68
70	Monozygotic Twins Display Different Minor Histocompatibility Antigens.. <i>Blood</i> , 2009, 114, 4324-4324.	1.4	0
71	HY Disparity Influences Outcomes of HLA-Matched Unrelated Allo-HSCT.. <i>Blood</i> , 2009, 114, 4337-4337.	1.4	8
72	A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFR α -expressing patients. <i>British Journal of Haematology</i> , 2008, 141, 200-204.	2.5	74

#	ARTICLE	IF	CITATIONS
73	Incidence, Treatment and Outcome of Isolated Extramedullary Relapses after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic and Myeloid Leukemias: Single-Center Experience with 324 Patients. <i>Blood</i> , 2008, 112, 4302-4302.	1.4	1
74	Elastin metabolism is disrupted in patients after allogeneic hematopoietic stem cell transplantation (alloHSCT) for acute and chronic myeloid leukemia. <i>Medical Science Monitor</i> , 2008, 14, CR584-8.	1.1	0
75	Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. <i>Annals of Hematology</i> , 2007, 86, 677-683.	1.8	60
76	The results of imatinib therapy for patients with primary eosinophilic disorders. <i>European Journal of Haematology</i> , 2006, 76, 535-536.	2.2	22
77	The achievement of complete molecular remission after autologous stem cell transplantation for T-cell lymphoma with associated hypereosinophilia, rare aberration t(6;11) and elevated IL-4 and IgE. <i>Haematologica</i> , 2006, 91, ECR42.	3.5	2
78	Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. <i>Haematologica</i> , 2005, 90 Suppl, ECR33.	3.5	11
79	Clinical significance of elastin turnover-focus on diseases affecting elastic fibres. <i>Wiadomości Lekarskie</i> , 2004, 57, 360-3.	0.3	6
80	Safety and efficacy of hematopoietic stem cells mobilization in patients with multiple sclerosis. <i>Hematology</i> , 0, , 160222065902008.	1.5	1
81	Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , 1.	0.6	0